Moderna Announces Success of mRNA-1283 in Phase 3 Vaccine Trial

Thursday, 13 June 2024, 12:04
Moderna has reported positive results from the phase 3 trial of its mRNA-1283 COVID-19 vaccine, marking a significant milestone in vaccine development. The investigational next-generation vaccine has demonstrated effectiveness in meeting the primary efficacy endpoint, showing promise in combating the ongoing pandemic. This breakthrough indicates a potential advancement in global vaccination efforts against COVID-19, highlighting Moderna's innovative approach to vaccine development.
LivaRava Finance Meta Image
Moderna Announces Success of mRNA-1283 in Phase 3 Vaccine Trial

Moderna's mRNA-1283 Success

Moderna has reported positive results from the phase 3 trial of its next-generation COVID-19 vaccine, mRNA-1283.

Primary Efficacy Endpoint Met

Moderna announced that mRNA-1283 has successfully met its primary efficacy endpoint in the trial.

These results hold significant promise for combating the current global health crisis and advancing vaccination efforts.

Do you want to advertise here? Contact us

Related posts

Do you want to advertise here? Contact us
Do you want to advertise here? Contact us
Newsletter

We carefully select news from the world of finance and publish it for our users. We understand the importance of reliable and up-to-date information for people in the financial world. Do you want to receive news in a convenient format and always have it at hand — subscribe to our newsletter and make your analytical work more effective.

Subscribe